AstraZeneca: New Data Shows Tezspire's Role In Future COPD Treatment
20/5 03:38
(RTTNews) - The primary results from the Phase IIa COURSE trial showed that treatment with AstraZeneca and Amgen's Tezspire (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not sta...